NAGE — Niagen Bioscience, Inc.
—
Nasdaq ·
Materials ·
Chemicals ·
CIK 1386570 ·
Last close
$3.05
Market Cap
$241.33M
52W High
$10.06
52W Low
$2.87
ADV30
417,650
Next earnings
2026-11-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 29,785,000 | 19,314,000 | 700,000 | 963,000 | 106,589,000 | 66,740,000 | 24,061,000 |
| Mar 2026 | 31,474,000 | 19,976,000 | 1,576,000 | 6,318,000 | 114,329,000 | 66,397,000 | 31,999,000 |
| Dec 2025 | 33,839,000 | 21,704,000 | 2,103,000 | 4,132,000 | 106,406,000 | 64,636,000 | 29,873,000 |
| Sep 2025 | 33,986,000 | 21,928,000 | 4,236,000 | 4,578,000 | 98,139,000 | 64,138,000 | 27,463,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$5,949,000
Investing CF
$5,028,000
Financing CF
$-4,711,000
CapEx
$-275,000
Dividends Paid
—
Buybacks
$-5,121,000
EPS Diluted TTM
$0.18
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-157,247,000
Inventory
$20,640,000
Receivables
$8,580,000
ST Investments
—
EBIT TTM
$8,615,000
Pretax Income TTM
$17,028,000
Interest Exp TTM
—
Analysts
6
Yahoo Snapshot (yfinance, live)
Total Revenue
$129,084,000
EBITDA
$9,591,000
Free Cash Flow
$1,641,375
Enterprise Value
$176,791,728
Total Cash
$66,588,000
Total Debt
$2,329,000
Shares Out
79,126,002
Trailing EPS
$0.19
Book Value
$1.04
ROE
21.8%
ROA
5.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 129,423,000 | 14,296,000 | 17,382,000 | 106,406,000 | 29,873,000 | 76,533,000 | 13,504,000 |
| Dec 2024 | 99,597,000 | 7,726,000 | 8,550,000 | 68,278,000 | 22,184,000 | 46,094,000 | 12,109,000 |
| Dec 2023 | 83,570,000 | -5,599,000 | -4,938,000 | 54,964,000 | 26,508,000 | 28,456,000 | 7,117,000 |
| Dec 2022 | 72,050,000 | -18,628,000 | -16,540,000 | 54,057,000 | 25,385,000 | 28,672,000 | -15,098,000 |
TTM Snapshot
Revenues TTM
$56,061,000
NetIncome TTM
$6,941,000
OpCashFlow TTM
$0
Assets (Latest)
$106,406,000
Forward EPS
$0.10
Max Pain — expiry 2026-11-20
max pain strike: $2.50 · spot: $2.99 · call oi: 2,605 · put oi: 100
Expected Move to 2026-11-20:
±$1.02
(34.11%) —
implied range
$1.97 –
$4.01
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LTBR | LIGHTBRIDGE Corp | $241.37M | $6.85 | — |
| FF | FutureFuel Corp. | $224.58M | $5.12 | — |
| ACB | AURORA CANNABIS INC | $259.57M | $4.10 | — |
| BAK | BRASKEM SA | $265.70M | $1.54 | — |
| USNA | USANA HEALTH SCIENCES INC | $267.91M | $14.50 | — |
News headlines (Yahoo Finance, 1h cache)
Niagen Bioscience Engages Veteran Pharmaceutical Executives and Biotechnology Experts to Support Drug Development Program and Strategic Business Growth
2026-09-17 12:32 · Yahoo
Niagen Bioscience to Present at Longevity Investors Conference
2026-09-02 12:32 · Yahoo
Niagen Bioscience to Present at Nasdaq X LD Micro Inaugural SF Summit
2026-08-26 12:32 · Yahoo
Niagen Bioscience to Present at the 17th Annual Midwest IDEAS Investor Conference
2026-08-12 12:32 · Yahoo
Niagen Bioscience Launches Tru Niagen on Walmart.com, Expanding Access and Diversifying Its E-commerce Marketplace Presence
2026-08-06 12:34 · Yahoo
Niagen Bioscience (NAGE) On New Aging Study And The Case For A Higher Fair Value
2026-08-06 06:10 · Yahoo
Niagen Bioscience Inc (NAGE) (Q2 2026) Earnings Call Highlights: E-Commerce Surge and China ...
2026-08-05 05:04 · Yahoo
Niagen Bioscience (NAGE) Meets Q2 Earnings Estimates
2026-08-04 21:40 · Yahoo
Niagen Bioscience Announces a Newly Published Analysis of Past Clinical Studies Demonstrating Niagen® (Patented Nicotinamide Riboside, NR) Supplementation Improved a Muscle-Specific Marker of Biologic
2026-07-28 12:32 · Yahoo
Niagen Bioscience to Present at Canaccord Genuity’s 46th Annual Growth Conference
2026-07-27 12:32 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.